-
公开(公告)号：US20090258884A1
公开(公告)日：2009-10-15
申请号：US12386336
申请日：2009-04-16
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, JR.
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, JR.
IPC分类号： A61K31/497 , C07D213/56 , A61K31/4412 , C07C235/00 , A61K31/165 , C07D401/12 , A61K31/444 , A61K31/4439 , A61K31/506 , C07D249/04 , A61K31/4192 , C07D409/12 , A61K31/4436 , C07D413/12 , A61K31/4709 , A61P3/04
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
-
公开(公告)号：US06972295B2
公开(公告)日：2005-12-06
申请号：US10387265
申请日：2003-03-12
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, Jr.
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, Jr.
IPC分类号： A61K31/165 , A61K31/27 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/415 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/423 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4436 , A61K31/445 , A61K31/4453 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/5377 , A61K31/553 , A61P1/04 , A61P1/10 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/24 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/06 , A61P13/12 , A61P15/00 , A61P15/10 , A61P17/00 , A61P19/02 , A61P19/06 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/16 , A61P25/18 , C07C233/12 , C07C233/13 , C07C235/06 , C07C235/18 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C323/41 , C07D207/27 , C07D209/08 , C07D209/34 , C07D209/52 , C07D209/94 , C07D211/34 , C07D213/36 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/89 , C07D215/06 , C07D231/12 , C07D233/36 , C07D233/70 , C07D233/80 , C07D237/14 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D249/18 , C07D261/08 , C07D261/20 , C07D263/58 , C07D267/14 , C07D277/20 , C07D277/30 , C07D277/36 , C07D277/64 , C07D277/74 , C07D295/12 , C07D295/13 , C07D295/14 , C07D295/15 , C07D401/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07D513/04 , C07D521/00 , A61K31/4412 , C07D213/70
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗物质滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。
-
公开(公告)号：US07816534B2
公开(公告)日：2010-10-19
申请号：US12386336
申请日：2009-04-16
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, Jr.
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, Jr.
IPC分类号： A61K31/44 , C07D213/04 , C07D401/02 , C07D403/02 , C07D239/02
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。
-
公开(公告)号：US07550489B2
公开(公告)日：2009-06-23
申请号：US12012463
申请日：2008-02-01
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, Jr.
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza, Jr.
IPC分类号： A61K31/435
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
-
公开(公告)号：US20080171692A1
公开(公告)日：2008-07-17
申请号：US12012463
申请日：2008-02-01
申请人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza
发明人： William K. Hagmann , Linus S. Lin , Shrenik K. Shah , Ravindra N. Guthikonda , Hongbo Qi , Linda L. Chang , Ping Liu , Helen M. Armstrong , James P. Jewell , Thomas J. Lanza
IPC分类号： A61K38/22 , A61K31/44 , A61K31/444 , A61K31/4439 , A61K31/365 , A61P3/04 , A61K31/485 , A61K31/357 , A61K31/155
CPC分类号： C07D213/64 , C07C233/13 , C07C235/06 , C07C235/20 , C07C235/34 , C07C235/74 , C07C235/78 , C07C237/06 , C07C255/55 , C07C255/60 , C07C271/14 , C07C271/22 , C07C275/30 , C07C311/03 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D209/34 , C07D209/94 , C07D211/34 , C07D213/65 , C07D213/68 , C07D215/06 , C07D231/12 , C07D233/56 , C07D233/70 , C07D237/28 , C07D237/32 , C07D239/34 , C07D249/04 , C07D249/08 , C07D249/12 , C07D263/58 , C07D267/14 , C07D277/30 , C07D277/36 , C07D295/13 , C07D295/15 , C07D513/04
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
-
公开(公告)号：US07754188B2
公开(公告)日：2010-07-13
申请号：US10559228
申请日：2004-06-25
申请人： H. Donald Burns , Alex M. Chen , Raymond E. Gibson , Mark T. Goulet , William K. Hagmann , Terence G. Hamill , James P. Jewell , Linus S. Lin , Ping Liu , Andrey V. Peresypkin
发明人： H. Donald Burns , Alex M. Chen , Raymond E. Gibson , Mark T. Goulet , William K. Hagmann , Terence G. Hamill , James P. Jewell , Linus S. Lin , Ping Liu , Andrey V. Peresypkin
CPC分类号： C07D213/64 , A61K51/0406 , A61K51/0455 , A61K51/0459 , C07D239/34
摘要： The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.
摘要翻译： 本发明涉及特定的放射性标记的大麻素-1（CB1）受体调节剂，以及使用这些调节剂用于哺乳动物，特别是人类中大麻素-1受体的标记和诊断成像的方法。 此外，还公开了可用于合成放射性标记的大麻素-1受体调节剂的中间体，以及合成放射性标记的大麻素-1受体调节剂的方法。 此外，描述了放射性标记的大麻素-1受体化合物的制剂。
-
公开(公告)号：US07514409B2
公开(公告)日：2009-04-07
申请号：US10591820
申请日：2005-03-07
申请人： William K. Hagmann , Linus S. Lin , Ping Liu , Richard A. Mumford , Thomas S. Reger , Nicholas D. Smith , Nicholas S. Stock , Jasmine Zunic
发明人： William K. Hagmann , Linus S. Lin , Ping Liu , Richard A. Mumford , Thomas S. Reger , Nicholas D. Smith , Nicholas S. Stock , Jasmine Zunic
IPC分类号： A61K38/05
CPC分类号： C07K5/06026 , C07D401/12 , C07D401/14
摘要： Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.
摘要翻译： 式I的化合物是VLA-4的拮抗剂，因此可用于抑制或预防细胞粘附和细胞粘附介导的病症。 这些化合物可以配制成药物组合物，并且适用于治疗包括溃疡性结肠炎和克罗恩病，多发性硬化，哮喘和类风湿性关节炎的炎性肠病。
-
8.发明授权Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators 有权取代的二氮杂类磺酰胺作为铃蟾肽受体亚型-3调节剂公开(公告)号：US08153626B2
公开(公告)日：2012-04-10
申请号：US12517836
申请日：2007-12-07
申请人： Robert K. Baker , Linda L. Chang , Marc Chioda , Harry R. Chobanian , Ying-Duo Gao , Yan Guo , Linus S. Lin , Ping Liu , Ravi P. Nargund , Kathleen M. Rupprecht , Shouwu Miao
发明人： Robert K. Baker , Linda L. Chang , Marc Chioda , Harry R. Chobanian , Ying-Duo Gao , Yan Guo , Linus S. Lin , Ping Liu , Ravi P. Nargund , Kathleen M. Rupprecht , Shouwu Miao
IPC分类号： A01N43/62 , A61K31/55 , C07D491/00 , C07D513/00 , C07D515/00 , C07D243/10 , C07D487/12
CPC分类号： C07D471/04 , C07D471/14
摘要： Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
摘要翻译： 某些新型取代的二氮杂类磺酰胺是人类bombesin受体的配体，特别是人类bombesin受体亚型-3（BRS-3）的选择性配体。 因此，它们可用于治疗，控制或预防对调节BRS-3的疾病和病症，例如肥胖症和糖尿病。
-
9.发明申请SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS 有权替代亚硫酸荧光素作为BOMBESIN受体亚型1调节剂公开(公告)号：US20100317645A1
公开(公告)日：2010-12-16
申请号：US12517836
申请日：2007-12-07
申请人： Robert K. Baker , Linda L. Chang , Marc Chioda , Harry R. Chobanian , Ying-Duo Gao , Yan Guo , Linus S. Lin , Ping Liu , Ravi P. Nargund , Kathleen M. Rupprecht , Shouwu Miao
发明人： Robert K. Baker , Linda L. Chang , Marc Chioda , Harry R. Chobanian , Ying-Duo Gao , Yan Guo , Linus S. Lin , Ping Liu , Ravi P. Nargund , Kathleen M. Rupprecht , Shouwu Miao
IPC分类号： A61K31/551 , C07D487/04 , C07D498/14 , C07D487/14 , A61P3/10 , A61P3/04
CPC分类号： C07D471/04 , C07D471/14
摘要： Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
摘要翻译： 某些新型取代的二氮杂类磺酰胺是人类bombesin受体的配体，特别是人类bombesin受体亚型-3（BRS-3）的选择性配体。 因此，它们可用于治疗，控制或预防对调节BRS-3的疾病和病症，例如肥胖症和糖尿病。
-
10.发明申请公开(公告)号：US20130030000A1
公开(公告)日：2013-01-31
申请号：US13574303
申请日：2011-01-25
申请人： Harry R. Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo , Terence G. Hamill , Wenping Li , Darrell Arthur Henze
发明人： Harry R. Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo , Terence G. Hamill , Wenping Li , Darrell Arthur Henze
IPC分类号： A61K31/497 , A61K31/506 , A61K31/513 , A61K31/4439 , A61K31/421 , A61K31/4245 , A61K31/4545 , A61K31/501 , A61K31/4725 , A61K31/4709 , A61P29/00 , A61P25/22 , A61P3/04 , A61P27/02 , A61P11/06 , A61P27/06 , A61P9/00 , A61P25/24 , A61P43/00 , A61P19/02 , A61P25/28 , A61P25/18 , A61P25/30 , A61P25/16 , A61P25/08 , A61P11/00 , A61P35/00 , A61P1/00 , A61P1/04 , A61P1/12 , A61P17/04 , A61P1/16 , A61P25/06 , A61P25/02 , A61K31/444
CPC分类号： A61K31/422 , A61K31/4178
摘要： The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.
摘要翻译： 本发明涉及可用于治疗包含选择的咪唑或恶唑FAAH抑制剂和第二活性剂的FAAH介导的疾病，病症或包含FAAH抑制剂和第二活化的病症的组合物。 该组合物可用于治疗广泛的疾病，病症或病症，包括骨关节炎，类风湿性关节炎，糖尿病性神经病，带状疱疹后神经痛，肌肉痛和纤维肌痛，以及急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病 ，和帕金森病。 另一方面，本发明公开了本发明涉及用于治疗神经性疼痛和伤害性疼痛的组合物，所述组合物包含埃托考昔。
-
-
-
-
-
-
-
-
-
搜索结果
465 条记录 (耗时 0.046 秒)
